Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22778695 | 0.89 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL22752552 | 0.84 | ESR1 (0.36) | ESR1ESR2 | |
| SCHEMBL22752558 | 0.84 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL19251352 | 0.83 | NPC1 (0.32) | — | |
| SCHEMBL22778709 | 0.83 | CNR2 (0.36) | — | |
| SCHEMBL12459180 | 0.80 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL22752318 | 0.79 | AOC3 (0.31) | — | |
| SCHEMBL22752323 | 0.76 | CNR2 (0.33) | ESR1ESR2 | |
| SCHEMBL22778707 | 0.76 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL12470737 | 0.76 | ESR1 (0.31) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | ESR1 4060/4885ESR2 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.